RxDoctor Payments Data

Daniel Kelly, MD

Family Medicine · Round Rock, TXNPI 1154689917

Payments from drug & device makers

$880in general payments, 2019–2025

Across 11 payments — averaging $79.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$273
  • Gilead$232
  • Welch Allyn$186
  • GSK$124
  • Abbott$36
  • Dexcom, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$66275%
  • Education$324%
  • Other$18621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$273
Gilead2$232
Welch Allyn1$186
GSK1$124
Abbott2$36
Dexcom, Inc.1$15
AstraZeneca1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$880 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,206
Medicare patients
208
Services billed
1,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$147,628
JardianceEmpagliflozin28$45,834
MounjaroTirzepatide25$27,520
XareltoRivaroxaban19$22,791
TrulicityDulaglutide11$21,350
RybelsusSemaglutide12$13,841
Breo ElliptaFluticasone/Vilanterol14$13,107
FarxigaDapagliflozin Propanediol13$12,459
Atorvastatin Calcium504$3,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,114
Losartan Potassium186$1,990
Metoprolol Succinate127$1,958
Levothyroxine Sodium183$1,929
ValacyclovirValacyclovir Hcl44$1,863
Celecoxib26$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$273$161,469116 claims
GSKBreo Ellipta$124$13,10714 claims
AstraZenecaFarxiga$14$12,45913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →